Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia

Equality Impact Assessment (Guidance development) (PDF 145 KB)

Final draft guidance

Final appraisal document (PDF 256 KB)

Committee papers (PDF 8.26 MB)

Final scope (PDF 233 KB)

Final stakeholder list (PDF 193 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 383 KB)

Draft scope post referral (PDF 281 KB)